OncoMatch/Clinical Trials/NCT07179679
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
Is NCT07179679 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TQB2934 for multiple myeloma.
Treatment: TQB2934 — TQB2934 is an anti-Cluster of Differentiation 3 (CD3) (Early T Cell Marker)×B cell maturation antigen (BCMA) double-specific antibody，and the isoform is IgG1(Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells. TQB2934 for injection (subcutaneous injection) is intended for the treatment of patients with multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: proteasome inhibitor
at least one proteasome inhibitor (PI)...are refractory
Must have received: immunomodulator
at least one...immunomodulator (IMiD)...are refractory
Must have received: CD38 monoclonal antibody
at least one...Cluster of Differentiation 38 (CD38) monoclonal antibody are refractory
Cannot have received: allogeneic hematopoietic stem cell transplantation
Exception: within 1 year before the first medication
Have received allogeneic hematopoietic stem cell transplantation within 1 year before the first medication
Cannot have received: autologous hematopoietic stem cell transplantation
Exception: within 12 weeks before the first medication
have received autologous hematopoietic stem cell transplantation (ASCT) within 12 weeks before the first medication
Cannot have received: CD3×BCMA dual antibody therapy
Have received CD3×BCMA dual anti-anti-treatment in the past
Cannot have received: glucocorticoid (dexamethasone)
Exception: cumulative dose >160 mg or equivalent within 4 weeks before the first medication
Cumulative treatment of dexamethasone >160 mg or equivalent dose of other glucocorticoids within 4 weeks before the first medication
Cannot have received: targeted therapy
Exception: within 3 weeks before the first medication
received targeted therapy, cytotoxic drugs or any antibody therapy within 3 weeks before the first medication
Cannot have received: cytotoxic chemotherapy
Exception: within 3 weeks before the first medication
received targeted therapy, cytotoxic drugs or any antibody therapy within 3 weeks before the first medication
Cannot have received: antibody therapy
Exception: within 3 weeks before the first medication
received targeted therapy, cytotoxic drugs or any antibody therapy within 3 weeks before the first medication
Cannot have received: proteasome inhibitor
Exception: within 2 weeks before the first medication
received proteasome inhibitor therapy or radiotherapy within 2 weeks before the first medication
Cannot have received: radiation therapy
Exception: within 2 weeks before the first medication
received proteasome inhibitor therapy or radiotherapy within 2 weeks before the first medication
Cannot have received: immunomodulator
Exception: within 1 week before the first medication
received immunomodulatory therapy within 1 week before the first medication
Cannot have received: Chinese patent medicine with anti-tumor indications
Exception: within 2 weeks before the first medication
received Chinese patent medicine treatments within 2 weeks before the first medication have received National Medical Products Administration (NMPA) -approved drug instructions that clearly have anti-tumor indications
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify